Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy, Lord, Joanne, Middleton, Calley, Szlosarek, Peter, Chan, Sam, Gaba, Aarti, Darlison, Liz, Wells-Jordan, Peter, Richards, Cathy, Poile, Charlotte, Lester, Jason F, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560642/
https://www.ncbi.nlm.nih.gov/pubmed/34656227
http://dx.doi.org/10.1016/S1470-2045(21)00471-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560642/
https://www.ncbi.nlm.nih.gov/pubmed/34656227
http://dx.doi.org/10.1016/S1470-2045(21)00471-X

Ejemplares similares